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ABSTRACT

Role of AMPK in the Upregulation of Steroidogenic Acute
Regulatory Protein in the Zona Fasciculata
of the Adrenal Cortex

Adam Dayton
Physiology and Developmental Biology
Master of Science

Cortisol is a glucocorticoid produced by the zona fasciculata (ZF) of the adrenal cortex.
Traditionally, cortisol production and release was seen as being regulated strictly by
adrenocorticotropic hormone (ACTH). While this is true of baseline cortisol levels and in
response to acute mental stress, the picture is somewhat more complicated in other situations.
Interleukin-6 (IL-6) contributes to the maintenance of cortisol levels in situations of
prolonged immune or inflammatory stress. AMP activated protein kinase (AMPK) was
investigated as a possible mediator of the action of IL-6 or as an independent actor in raising
cortisol levels in response to hypoxemic or hypoglycemic stress.
5-aminoimidazole-4-carboxamide 1-b-D-ribofuranoside (AICAR) was used to activate
AMPK. Bovine ZF tissue fragments were exposed to AICAR alone and together with a known
AMPK inhibitor, compound C. Protein or mRNA was then extracted from these tissue
fragments. As an indicator of overall steroidogenic activity, these extracts were tested using RTPCR and western blot assays for relative protein and mRNA levels of steroidogenic acute
regulatory (StAR) protein, steroidogenic factor-1 (SF-1), and dosage sensitive sex reversal
adrenal hypoplasia congenita gene on the X chromosome, gene 1 (DAX-1). Also a reporter gene
assay was performed on H295R cells with a transfected StAR promoter.
In bovine ZF tissue fragments, AICAR caused a significant increase of StAR protein and
mRNA and SF-1 protein with a decrease of DAX-1 protein in a dose and time dependant
manner. DAX-1 mRNA was shown to decrease in response to AICAR administration in a dose
dependant manner. AICAR induced increases in StAR protein and SF-1 protein, and the

attendant decrease in DAX-1 protein were all shown to be reduced by administration of
compound C. This demonstrated that in this situation AICAR is acting through AMPK. When
IL-6 was given with compound C the levels of StAR, SF-1, and DAX-1 were significantly
reduced from samples treated with IL-6 alone. AICAR exposure also increased StAR promoter
activity in a dose and time dependant manner. This AMPK induced increase in steroidogenic
activity provides a possible mechanism for increased cortisol during hypoxia and hypoglycemia,
and a possible mediator for IL-6 in the ZF.

Keywords: ACTH, Adrenal, Cortex, AMPK, Zona Fasciculata, ZF, Cortisol, StAR, Hypoxia,
Hypoglycemia, SF-1, DAX-1, IL-6, Steroidogenesis
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INTRODUCTION
Cortisol is released from the adrenal cortex and plays a key role in mediating the
physiological response to stress. Various pathophysiological conditions result if cortisol release
is either elevated (i.e. inhibition of immune function, emotional instability, coronary artery
disease) or inhibited (i.e. autoimmune and inflammatory diseases, low blood glucose, collapse of
the circulatory system resulting in shock). The release of cortisol during acute stress is regulated
by the hormone ACTH from the anterior pituitary. However, during chronic stress related to
inflammation and infection, ACTH’s role in regulating cortisol release has been demonstrated to
be diminished because plasma cortisol concentrations stay elevated whereas ACTH
concentrations are normal (1). During chronic inflammatory stress the release of cortisol appears
to be mediated by various cytokines (protein hormones that are released from several tissues of
the body including the immune system and adipose tissue) (2). Particularly, the cytokine
interleukin-6 (IL-6) has been shown to play a key role in regulating the release of cortisol during
chronic stress related to inflammation and infection (3). We have found that this IL-6 induced
increase in cortisol secretion is mediated in part through IL-6 upregulating the expression of the
steroidogenic acute regulatory protein (StAR). The action of StAR is the rate limiting step in the
synthesis of most steroids including cortisol (4). Control of transcription of StAR and many
other steroidogenic proteins has been closely influenced by steroidogenic factor-1 (SF-1) and
dosage sensitive sex reversal adrenal hypoplasia congenita gene on the X chromosome, gene 1
(DAX-1). While SF-1 up-regulates steroidogenic transcription, including StAR, DAX-1 has an
opposing effect (5).
Cortisol helps maintain the body’s responsiveness to stress, and one important role in this
buildup of stress responsiveness is the maintenance of blood glucose. Cortisol accomplishes this
1

partially by reducing insulin sensitivity and increasing sensitivity to epinephrine. ACTH is
elevated during hypoglycemia (6, 7), and this in turn would stimulate the zona fasciculata and
would cause increased cortisol in order to try and bring blood sugar back up. There is some
evidence that cortisol increase in response to hypoglycemia can be attributed to more than ACTH
alone (8). It has been found that AMP activated protein kinase (AMPK) can act as the sensor of
blood sugar levels in the hypothalamus that eventually leads to greater ACTH release (9). We
have recently found that AMPK is present in the adrenal cortex, and we wanted to investigate if
AMPK activation in the adrenal cortex can act as a direct activator for StAR production in the
adrenal.
In addition to inflammatory, immune, and hypoglycemic stress, ACTH does not appear to
be the only factor in regulating cortisol release during hypoxemic stress (decreased oxygen in the
blood) (10,11). The mechanism for adrenal detection of hypoxia is currently unknown. It has
been found that actions similar to that of IL-6 in many tissues can be accomplished by activation
of AMPK (12). It has even been demonstrated in a few tissues that IL-6 action can be mediated
directly by activation of AMPK (13, 14, 15, 16). AMPK is an energy sensing enzyme that is
activated when the intracellular ratio AMP/ATP is elevated. A lack of oxygen in the blood
would reduce cellular respiration causing the ratio of AMP to ATP to rise and allow AMPK to
act as a sensor for hypoxia. There is some evidence that exposure of bovine adrenocortical tissue
to 5-aminoimidazole-4-carboxamide 1-b-D-ribofuranoside (AICAR), an AMPK activator,
increases the expression of StAR. From this information we look to AMPK to possibly serve as
the link between hypoxia and the release of glucocorticoids.
In order to make certain that AICAR was acting on AMPK we used the AMPK inhibitor
compound C. Compound C has unfortunately been found to have some broad effects on
2

inhibiting cytokine production, inhibiting glycolysis, and affecting other areas like AP-1 action
(17, 18). However this is the best compound available to inhibit AMPK. We will also use
compound C to determine AMPK’s relationship with IL-6.
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MATERIALS AND METHODS
MEDIA
DMEM/F12
The DMEM/F12 was purchased from GIBCO (cat# 11330-032). It was supplemented
with Cosmic Calf Serum from HyClone (SH300087.04), 10,000 IU/ml penicillin G sodium and
10,000 µg/ml streptomycin sulfate from GIBCO (15140-122) diluted 20 times, and insulintransferrin-sodium-selenite (ITS). To complete 500 ml of DMEM/F12 medium 26.5 ml of
Cosmic Calf Serum, 150 µl of penicillin-streptomycin mix (8 ml dH2O with 200 mg
streptomycin sulfate, 500 mg penicillin G, 400 mg gentamycin, and 15 mg amphotericin B), and
530 µl of ITS were added. Completion of medium was done as needed and only 500 ml were
completed at one time. The complete and incomplete DMEM/F12 were stored in the refrigerator
at a temperature of 0º - 4º C.
RPMI
RPMI Medium 1640 was purchased from GIBCO (31800-089) in powder form. To make
500 ml of RPMI medium, 5.20 g of powder were dissolved in sterile water using a stir bar at
room temperature. To this solution was added 1.0 g NAHCO3. The pH of the medium was then
adjusted to 7.2 using NaOH and HCl. The pH was adjusted slightly lower than desired as per the
instructions that came with the RPMI, which indicated that the pH of the solution would go up
0.1-0.3 pH units upon filtration. After adjusting the pH, the RPMI medium was filter sterilized
using a vacuum filter in a sterile hood. The RPMI Medium 1640 was stored in a refrigerator at a
temperature of 0º - 4º C.
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H295R CULTURED CELLS
H295R cultured cells (American Type Culture Collection, Manassas, VA) were incubated
in DMEM/F12 complete medium. Five ml of DMEM/F12 complete was added to every 100 mm
culture plate. The H295R cells were grown on plates in an incubator set to 36.9º C and 5% CO2.
Cells were treated when they were approximately 75% confluent.
BOVINE ADRENAL ZONA FASCICULATA FRAGMENTS
Bovine adrenal glands were collected from the Deseret Meat slaughterhouse in Spanish
Fork. Adrenals were cut out of the cow shortly after it was killed and placed in 1X PBS on ice.
Samples were brought back to the lab and were sliced and the zona fasciculata (ZF) was
dissected out from the rest of the cortex. Once separated, the ZF was cut into small fragments
and placed in RPMI and placed in a shaking water bath at 37º C with oxygen for 30 min to
equilibrate before getting treated. Time from death of the cow to treatment was usually 2 to 2 ½
hours and never more than 4 ½ hours.
TREATMENTS
Bovine Time Course
After equilibrating in RPMI at 37º C, half of the tissue fragments were treated with
AICAR at 1mM concentration in RPMI. The other half were given a new round of RPMI
without AICAR. One sample of each type was taken out of the treatment solution and frozen
after 30 min, 60 min, and 180 min of treatment. All samples were given oxygen during the
whole treatment period. Each sample contained ~100mg of tissue.
Bovine Dose Response
After equilibrating in RPMI at 37º C samples were treated for 1 hour with varying doses
of AICAR dissolved in 2 ml RPMI medium. One sample was given only RPMI medium and
5

samples 2-6 were given AICAR in the following doses: 0.1 mM, 0.3 mM, 0.5 mM, 1.0 mM, and
3.0 mM. All samples were given oxygen during the whole treatment period. Each sample
contained ~100mg of tissue.
Experiments with AICAR and Compound C
These experiments were performed using bovine adrenal tissue fragments. After
equilibrating in RPMI at 37º C, half the samples were treated for 30 min with RPMI with 1%
DMSO while the other half were treated with 1 mM compound C dissolved in DMSO and added
to RPMI to make a final concentration 10 µM compound C in 1% DMSO RPMI. After this pre
treatment with compound C, samples were treated with either RPMI with 1% DMSO only, 1mM
of AICAR dissolved in RPMI medium with 1% DMSO, compound C as described above, or
both AICAR and compound C in RPMI with 1% DMSO. All samples were given oxygen during
the whole treatment period. Each sample contained ~100mg of tissue.
Luciferase Reporter Gene Assay
Cultured H295R cells were transfected with 4 µg of the luciferase gene containing
plasmid (pGl2), or 12 µg of a 6456 base pair pGL2 plasmid modified to contain the StAR
promoter region (-858bp), and 7 µg of a β-galactosidase expression plasmid as an indicator of
transfection efficiency.
Lipofectamine-PLUS Reagents (Invitrogen, Carlsbad, CA) were used to transfect the
cells according to instructions given by manufacturer. A 12-well plate was seeded with 1.25 x
105 cells and incubated 18-24 hours with complete DMEM/F12 media. A solution of 0.6%
PLUS reagent and plasmid DNA was incubated in DMEM/F12 supplemented with only ITS for
each plasmid for 15 minutes at room temperature together with a 0.6% Lipofectamine solution.
While this complete transfection solution was incubating, 400 µl of DMEM/F12 + ITS was
6

added to each well. After its incubation, the transfection mix was added in 100 µl aliquots to
each well and incubated for 5-6 hours. This solution was removed and 1ml of 2X Serum
DMEM/F12 media supplemented with Nu Serum only was added to each well and cells were
incubated for 18-24 hours. Media was then exchanged for DMEM/F12 + ITS to incubate for 15
– 30 min. Cells were then treated with either a variable dose of AICAR dissolved in DMEM/F12
(Control, 0.5 mM, 1.0 mM, 1.5 mM, 2.0 mM) for 60 min or with 1mM of AICAR for variable
amount of time (30 min, 60 min, and 120 min) for both control and AICAR treated. Each group
included the following controls: cells transfected with the basic plasmid treated with DMEM/F12
alone, cells transfected with StAR plasmids treated with DMEM/F12 alone, and cells transfected
with β-gal plasmids treated with DMEM/F12 alone. At the completion of treatment, cells were
rinsed with cold PBS then 75 µl of cell extraction solution (83 mM K2HPO4, 16.63 mM
KH2PO4) was added to each well. Cells were scraped into a micro centrifuge tube and
centrifuged at 12,000 G for 10 min to pellet debris. Luciferase measurement is explained below.
ANALYSES
RT-PCR
mRNA Extraction
Bovine ZF tissue fragments were treated as described above and mRNA was extracted
from these fragments using TRI Reagent (Sigma Aldrich T9424). Tissue was placed in a glass
homogenizer with 0.5 ml of TRI and homogenized. The mixture was poured into a 1.5 ml
centrifuge tube and the homogenizer was rinsed with another 0.5 ml of TRI and this was added
to the same centrifuge tube. This solution was incubated for 5 min at room temp to allow
complete breakdown of nucleoprotein complex. 0.2 ml chloroform was added to each sample
and each was inverted and shaken. All samples were then centrifuged at 12,000 G for 20 min.
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After centrifuging, the top aqueous layer was removed and placed into new 1.5 ml centrifuge
tubes, and the other layers were discarded. The mRNA was then precipitated by adding 0.5 ml
isopropanol and inverting and shaking. Samples were left at room temp for 10 minutes to allow
precipitation reaction to progress. Samples were then centrifuged at 12,000 G for 15 min.
Following centrifuging, the supernatant was discarded, and 1 ml 75% ethanol was added to each
tube. After shaking each tube vigorously they were centrifuged at 7500 G for 5 min. Following
centrifuging, supernatant was poured out and samples were allowed to air dry on ice between 5
and 10 minutes. Resulting mRNA pellets were dissolved in 50 µl of nuclease-free water (NFW),
and warmed in a 60º water bath for 15 min.
mRNA Quantification
Concentration was quantified using the ND-1000 spectrophotometer from Nanodrop.
Using NFW as a blank, 2 µl of each sample was placed on the Nanodrop which determined the
concentration of mRNA. Samples were diluted to obtain a working concentration between 1000
and 2000 µg/ml.
Reverse Transcription Reaction
A grand mixture was made that contained the exact ratio of the following: 1.0 µl 10x
Buffer, 1.0 µl dithiothreitol (DTT), 0.5 µl Superscript II (reverse transcriptase), 0.5 µl dNTP
(deoxynucleotide triphosphates), 0.5 µl RNAse inhibitor, and 0.2 µl 10x decamer. This ratio was
multiplied by the number of samples being tested plus one. This grand mixture was combined in
a separate microcentrifuge tube, and 3.7 µl of the grand mixture was added to each sample tube.
2 µg of sample mRNA were added to each tube that now contained the grand mixture. NFW
was then added to bring each mixture to 10 µl total volume. The tubes were then vortexed,
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centrifuged, and placed in the thermocycler (Gene Amp PCR system 2400 Perkin Elmer,
Waltham, MA). Thermocycler was run at 42º C for 1 hour.
Polymerase Chain Reaction
A grand mixture was made for the completed RT samples with the following ratios of
solutions multiplied by the number of samples plus one: 19.9875 µl NFW, 2.5 µl 10x buffer,
0.3125 µl dNTP, 1.0 µl primer, 0.2 µl JStaq (DNA polymerase). A different grand mixture was
made for each primer (one for 18s control and one for the experimental primer). Aliquots (24 µl)
of the grand mixture were added to a microcentrifuge tube for each sample. To each of these
was added1 µl of the desired RT sample. After vortexing and centrifuging, the tubes were put in
the thermocycler (Gene Amp PCR system 2400 Perkin Elmer, Waltham, MA). Initially the
DNA would be denatured at a temperature of 95º C for 3 min. The machine would cycle through
the next 3 temperatures 35-55 times. First 95º C for 30 sec to separated the template and new
complementary strand, then from 56º-58º C depending on the length of primer for 30 sec to
allow the primer and coding strand to anneal, finally to 72º C for 45 sec for optimal polymerase
action. At the end of these cycles, the machine would hold at 72º for 3 min to allow completion
of polymerase reactions followed by being held indefinitely at 4º C to prevent further reactions
until PCR mixture was frozen again.
Electrophoresis
Agarose gels were prepared by adding 0.5 g of agarose to 50 ml of Tris-acetate EDTA
electrophoresis buffer (TAE) and microwaving for 1 min. After allowing the solution to cool for
3 min, 2.5 µl of ethydium bromide were added and the solution was swirled to mix. Mixture was
poured into gel apparatus, bubbles were removed, a 12 well comb was placed in the gel, and it
was allowed to harden. TAE was added to the electrophoresis apparatus until it covered the gel.
9

To 10 µl of each PCR sample was added 2.5 µl of loading dye, and each sample was then mixed
by vortexing. 10 µl of each sample and loading dye mix was then added to each well, and the
electrophoresis was run at 80 V for 40 min (sometimes a little more or less depending on the
sample being run).
The gel was photographed over transilluminating ultraviolet light, and the bands’ spot
density was quantified using a computer camera and software (Alpha Innotech Corporation,
Fluorchem 8900).
Western Blot
Protein Extraction
Bovine tissue was added to a homogenizer with 400 µl of extraction buffer (4 ml per
gram of tissue for 100 mg of tissue). Extraction buffer was made of a stock solution which
contained 0.79 g Tris-HCl, 4.6 g mannitol, 0.21 g NaF, 0.22 g sodium pyrophosphate, 0.037 g
EDTA, 0.038 g EGTA, 1 ml 100x Triton, 10 ml glycerol, and distilled water to a volume of 100
ml to which was added at the time of use 50 µl of 1 mM PMSF in isopropanol, 0.0154 g of DTT,
0.0156 g of benazamidine, and 0.1 mg soybean trypsin inhibitor. Homogenate was poured into
1.5 ml centrifuge tubes and incubated on ice for 60 min. Then homogenate samples were
centrifuged at 10,000 G for 10 minutes. The supernatant was retained and stored in the freezer at
-90º C. Protein concentration was determined by Bradford assay.
Electrophoresis
Samples were prepared by combining 10 µl of 4x loading buffer (50 ml 0.5 M Tris-HCl,
30 ml glycerol, 8 g SDS, ddH2O to 92 ml pH to 6.8 if necessary, and 20 mg bromophenol blue,
added 8% β-mercaptoethanol (e.g. 80 μl BME + 920 μl 92% 4x Loading buffer) right before
use), and a 30 µl mixture of sample and water that would contain 80 µg total protein. These 40
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µl mixtures were loaded into the 10% gels from BIO-RAD (161-1155) and run for ~30 min at
200 V in running buffer that was prepared from commercial 10x buffer concentrate from BIORAD (161-0732). After electrophoresis, gel cassettes were opened and the gels removed. The
wells were cut away from the body of the gel, and the gel was placed in transfer buffer (26.6 g
glycine, 6.06 g Tris-HCl, 400 ml methanol, brought to 2000 ml with distilled water) to soak for
~15 min. All filter papers and fiber pads needed for transfer were soaked in cold transfer buffer
for at least 45 min before transfer. After soaking transfer cassettes were assembled to transfer
proteins to a polyvinylidene fluoride (PVDF) membrane at 100 V for 60 min. After the transfer,
the membrane was stained with Ponceau S in 5% glacial acetic acid. This stained all proteins red
and allowed us to assess the equivalence of our protein loading for each sample.
Immunoblotting
After rinsing membranes in TBST (2.42 g Tris-HCl, 8.00 g NaCl, pH to 7.6 and bring to
1 L with distilled water, and add 1 ml of polyoxyethylene 20 sorbitan monolaurate (Tween)),
they were soaked in 5% dry milk/TBST to cover the membrane in non-specific milk protein for 1
hr. After blocking, the membranes were washed twice in TBST for 5 minutes each time. Then
the membranes were soaked in primary antibody solution (1 mg% BSA/TBST with 1:750 to
1:5000 ratio of antibody) overnight while covered at 4º C. The next morning the antibody
solution was removed and the membranes were rinsed 3 times for 5 min each in TBST. Then
membranes were incubated in HRP conjugated secondary antibody solution (1% dry milk/TBST
with 1:500 to 1:5000 ratio of antibody) for 60 min. After removing antibody solution, the
membrane was washed 3 times in TBST for 5 min each. Membranes were then soaked in
detection solution (western blotting luminal reagent, Santa Cruz Biotechnology, sc-2048) for 1-2
min. The membranes were placed in a plastic sheet protector and exposed to photo film (Classic
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Blue Autoradiography Film BX from Midsci) in a darkroom for 1-5 min depending on intensity
of bands. After processing with development machine, a picture was taken of the developed film
and density of bands was analyzed using Fluorchem 8900 software from Alpha Innotech.
Antibodies
Antibodies for StAR, SF-1, and DAX-1 were purchased from Santa Cruz Biotechnology.
The antibodies were rabbit anti-human, but they were used for, and bound to, bovine proteins.
Luciferase Report Gene Assay
β-galactosidase activity was measured using the Galacto-Light Plus system
(Tropix/Applied Biosystems, Foster City, CA) according to manufacturer’s instructions. 100 µl
reaction buffer (lactose substrate) added to 2 µ of each cell extract and incubated for 30 min.
Then 100 µl of accelerator (Tropix) was added to terminate enzyme activity ad initiate light
emission to be measured by the luminometer (TD-20/20 Turner Designs, Sunnyvale, CA).
Luciferase production in transfected cells was measured using the Luciferase Assay System
(Promega, Madison, WI). 100 µl of luciferase assay reagent containing luciferin substrate was
added to 20 µl of cell extract, and light produced from the luciferase reaction was measured by
the luminometer. Results were compiled on an Excel spreadsheet by calculating the ration of
Luciferase/β-galactosidase light production, listed as relative light units (RLU). Ratios were then
normalized to controls that had not received AICAR, and final numbers were given in terms of
fold RLU.
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RESULTS
In the first series of experiments, the concentration–related effect of AICAR on the
expression of StAR protein and mRNA was determined in fragments of bovine adrenal zona
fasciculata. StAR protein was increased in bovine ZF tissue fragments by AICAR administration
for 60 min in a dose dependent manner from 0.1 mM through 1.0 mM. Whereas, StAR protein
was increased in comparison to the control by all doses of AICAR, the StAR protein response
reached a plateau between 1 and 3 mM in that the response to 3.0 mM AICAR was not
significantly higher than that of 1.0 mM AICAR (FIGURE 1). In the next series of experiments,
the relationship between the incubation period of AICAR exposure and StAR protein expression
was determined. AICAR (1 mM) caused an increase in StAR protein levels in bovine ZF in a
time dependent manner beginning at 30 min and the augmentation of StAR expression continued
to increase through 180 min (FIGURE 2).
Similar to the effect on StAR protein, StAR mRNA was increased in bovine ZF tissue
fragments by AICAR administration for 60 min in a dose dependent manner from 0.1 mM
through 3.0 mM. StAR mRNA was increased in comparison to the control by 0.3 mM and
greater concentrations of AICAR (FIGURE 3). Likewise StAR mRNA was increased by 1.0
mM AICAR in a time dependent manner in that AICAR exposure for 30 min significantly
increased StAR mRNA expression and the effect at 60 min was significantly greater than the
effect at 30 min and the increase in expression at 180 min in turn was significantly greater than
the effect at 60 min. (FIGURE 4).
AICAR may increase StAR mRNA expression through induction of StAR mRNA
synthesis or though inhibition of mRNA degradation. In order to determine if AICAR was
directly altering StAR mRNA synthesis, a human adrenal tumor cells line that is easily
13

transfected with the StAR promoter coupled to luciferase was utilized. StAR promoter activity
was increased in cultured H295R cells in a time dependent manner by administration with 1.0
mM AICAR from 30 min to 120 min (FIGURE 5A). StAR promoter activity was increased in
cultured H295R cells by AICAR administration for 60 min in a dose dependent manner from at
least 1.0 mM AICAR to 1.5 mM AICAR. StAR promoter activity was not increased from
baseline levels with administration of 0.5 mM AICAR, and 2.0 mM AICAR produced a decrease
in activity from the level of 1.5 mM AICAR dose, though it was still significantly higher than
baseline activity. 1.5 mM AICAR was the maximal dose for StAR promoter activity (FIGURE
5B).
SF-1 is one nuclear factor among many that contributes to increased StAR production
(19, 20). Therefore, we were interested in the effects of AICAR on SF-1 expression.
SF-1 protein was increased in bovine ZF tissue fragments by AICAR administration for 60 min
in a dose dependent manner from 0.1 mM through 1.0 mM AICAR. Whereas SF-1 protein was
increased in comparison to the control by all doses of AICAR, the response to 3.0 mM AICAR
was not significantly higher than that of 1.0 mM AICAR (FIGURE 6). Similar to the effects of
AICAR on StAR protein, 1.0 mM AICAR caused an increase in SF-1 protein levels in bovine ZF
tissue fragments in a time dependent manner beginning at 30 min and continuing through 180
min (FIGURE 7).
The nuclear factor DAX-1 inhibits the expression of StAR and steroidogenic enzymes
and therefore is often increased when steroidogenesis is inhibited, and decreased when
steroidogenesis is stimulated. Therefore we determined the effects of AICAR on the expression
of DAX-1 protein and mRNA in the bovine adrenal ZF.
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DAX-1 protein was decreased in bovine ZF tissue fragments by AICAR administration
for 60 min in a dose dependent manner from 0.5 mM to 1.0 mM AICAR. The first concentration
of AICAR to significantly inhibit DAX-1 was 0.5 mM and the reduction reached a maximum at
1.0 mM. (FIGURE 8). The AICAR inhibition of DAX-1 expression was time dependent in that
a 30 min incubation with 1.0 mM AICAR administration caused a significant decrease in DAX-1
protein levels in bovine ZF tissue fragments and this inhibition became larger through 180 min
(FIGURE 9). The decrease in DAX-1 protein was accompanied by a decrease in DAX-1 mRNA
in that AICAR administration for 60 min decreased DAX-1 mRNA in a dose dependent manner
from 0.1 mm AICAR through 3.0 mM AICAR in bovine adrenal ZF fragments. (FIGURE 10).
In the next series of experiments, it was determined if the effects of AICAR on StAR
protein expression were due to some type of non-specific effect of the treatment or if they were
mediated by activation of the AMPK pathway. This was accomplished by exposing fragments of
bovine adrenal ZF tissue to compound C, a known inhibitor of AMPK, and then exposing these
tissues to AICAR. AICAR induced increases in StAR protein levels in bovine ZF tissue
fragments was reduced by pretreatment and coadministration of compound C (FIGURE 11) .
Likewise, AICAR induced increase of SF-1 protein expression in bovine ZF tissue fragments
was reduced by pretreatment and coadministration of compound C (FIGURE 12). Similar to the
effects on StAR and SF-1, the AICAR-induced decrease in DAX-1 protein levels in bovine ZF
tissue fragments was reduced by pretreatment and coadministration of compound C (FIGURE
13). All these results provide evidence that the AICAR effects on this tissue are mediated by
activation of the AMPK pathway.
In order to determine if IL-6 is increasing the expression of StAR through activation of
the AMPK pathway, fragments of bovine adrenal ZF were exposed to IL-6 in the presence or
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absence of compound C. As reported previously, IL-6 significantly increased StAR protein
expression in fragments of bovine ZF cells (21). This IL-6 induced increase in StAR protein
expression in bovine ZF tissue fragments was reduced by pretreatment and coadministration with
compound C (FIGURE 14).
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DISCUSSION
It has been noted that ACTH is not the only regulator of cortisol release from the ZF.
Particularly in situations of stress outside of acute mental stress (e.g., inflammation or other
insults to the immune system) there are other signaling agents that elevate cortisol production
and release. One of these mediators appears to be IL-6 (3). In other tissues, the effects of IL-6
are mediated at least in part through activation of the AMPK pathway (13, 14, 15, 16). AMPK
has always been known as an energy sensor that activates when the AMP: ATP ratio rises (22).
AMPK is active in numerous tissues and has been found to do much more than just turn off
energy consuming machinery and turn on energy producing machinery (23, 24). In some cases,
such as the IL-6 pathway, it has been found to be the mediator in the action of endogenous
signaling agents (13, 14, 15, 16). We wanted to see if AMPK activation caused increased StAR
in the ZF as an indicator of increased cortisol production. Though AMPK could also be acting
independently, we wanted to see if it played some role in the ZF’s response to IL-6 as it has been
shown to do in other tissues (12).
In this study, we have demonstrated that AICAR increases the expression of StAR
protein in a time and concentration dependant manner. Additionally, when compound C was
included with AICAR treatment, levels of StAR, SF-1, and DAX-1 protein were almost
completely returned to baseline. This made it clear that nearly all of the response produced by
AICAR treatment can be attributed to increased AMPK activity. The increase in StAR protein
expression is at least in part mediated by AICAR increasing the expression of StAR mRNA in
that AICAR increased StAR mRNA in a time and concentration dependent manner. The
increase of StAR protein to nearly 2 fold of baseline is quite large. In a similar manner, StAR
mRNA and promoter activity levels rise to about 2 fold of baseline. It was telling to note that in
17

the time course experiments for StAR that the rise in mRNA levels preceded a similar rise
further down the time scale for protein levels.
The increased expression of StAR mRNA by AICAR is at least in part mediated through
an increased synthesis of the StAR mRNA because AICAR contributed to an increase of StAR
promoter activity in a time and concentration dependent manner..
Therefore, activation of AMPK increases the expression of StAR and probably modifies
steroidogenesis.

The significance of this observation is supported by the observation that when

compound C was added to the IL-6 treatment StAR protein levels were brought down from 2
fold of baseline to just 1.2 of baseline. This clearly shows that AMPK plays a downstream role
in IL-6 induced increase of StAR protein. The mechanism through which this occurs in the
adrenal or other tissues is unknown (13-16).
In addition to the role of AMPK in IL-6 stimulation of adrenal function, the AMPK
pathway may also be involved in the modification of steroidogenesis in the adrenal by other
cytokines (2, 3, 13, 25, 26). AMPK’s role in raising StAR protein gives a possible mechanism
for cortisol elevation in response to hypoxia. This would provide a direct route for upregulation
of cortisol similar to that of IL-6 raising cortisol directly in response to inflammatory or immune
stress (3). It is clear that AMPK activity leads to greater production of StAR. This would likely
lead to more cortisol release, and this would provide a mechanism for direct cortisol increase in
hypoglycemic situations. This could have implications in the side effects of drugs that act on
AMPK like Metformin, and also in contributing to the possible causes of type II diabetes
mellitus.
The mechanisn through which AMPK increases StAR production is unknown. However,
AMPK increases the expression of SF-1 which increases the expression of StAR and
18

steroidogenic enzymes in many tissues (5, 19, 20). Similar to the increase of SF-1, a decrease in
DAX-1 leads to more expression of steroidogenic enzymes (5). In our results, SF-1 had an even
greater increase than that of StAR at about 2.25 fold of baseline at one hour. One interesting
feature of the results for SF-1 was that it continued to increase dramatically for 3 hours all the
way to 3.5 fold of baseline while StAR did not rise as much after 1 hour. Likewise, DAX-1
protein and mRNA dropped to less than half of baseline in 1 hour and then down to a third of
baseline after 3 hours of treatment. This trend is similar to that of continued change in levels
ofSF-1. For these to occur without an attendant increase in StAR protein and mRNA levels
seems counterintuitive. There may be other factors keeping the amount of StAR in check in light
of the continued rise of SF-1and fall of DAX-1. Possibilities include increased mRNA and
protein degradation. However, due to the lack of large increase from 60 minutes to 120 minutes
in StAR promoter activity there must be something repressing transcription in the first place.
This could be an inhibitor that is connected to StAR, cortisol, or SF-1 in a negative feedback
loop to prevent excessive steroidogenesis.
FUTURE EXPERIMENTS
The lab will continue to perform similar tests with AICAR, compound C, and IL-6 on
H295R cells and then test them for protein and mRNA levels of StAR, SF-1, and DAX-1. This
will provide a stronger connection to human adrenals than is given by the bovine data alone.
Also more results will be obtained for mRNA for DAX-1 and SF-1 to make sure the mRNA
picture matches up with the protein picture for these two nuclear factors. We so far have only
obtained IL-6 data for StAR as the results came just before printing this thesis we have yet to
receive the same data for SF-1 or DAX-1.
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We will also spend some time looking at other steroidogenic enzymes like P450scc, 17αhydroxylase, 2-hydroxylase, 3-β-hydroxyateroid dehydrogenase, and 11β-hydroxylase. This
along with a radioimmunoassay to test cortisol levels will give us a more complete picture of
AMPK’s influence on steroidogenesis.
From here we will also want to see what AMPK does in the ZR. Steroidogenesis in the
ZR was found to be reduced by IL-6. This is likely because the body does not want to dedicate
resources to reproductive activities when under immune stress. We suspect the same is likely to
be the case with hypoxia and hypoglycemia.
CONCLUSION
Cortisol is an important hormone with numerous roles in the body. Too much or too little
cortisol can be very detrimental to normal function of the body. AMPK plays a significant role
in the production of cortisol by causing an increase of StAR protein in the zona fasciculata of the
adrenal cortex. This may be in response to hypoxia or hypoglycemia, both of which are
situations known to cause increased cortisol. Also, AMPK acts as an intermediary for IL-6 in its
elevation of StAR in the ZF.
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FIGURE 1

30 kDa

a – p < 0.05 vs. control

b – p < 0.01 vs.
control
5, 12 – number of
individual
samples tested
under each
value

Figure 1: AICAR induces increased StAR protein levels in dose dependant manner
Bovine adrenal ZF tissue fragments were treated for 1 hour with increasing dosage of AICAR dissolved
in RPMI at 37º C. Following protein extraction, StAR protein levels were determined using western blot.
Primary StAR Antibodies (Santa Cruz) were used. Fold protein expression was detected using
luminol/stable peroxidase detection system (Santa Cruz). Levels were measured through use of the spot
density tool on the FluorChem 8900 Imaging System and each band was adjusted for local background.
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FIGURE 2

30 kDa

a, b, c, – p < 0.01 vs.
control of the
same time
point

Figure 2: AICAR induces increased StAR protein levels in time dependant manner
Bovine adrenal ZF tissue fragments were treated with RPMI only or 1 mM AICAR dissolved in RPMI at
37º C for increasing lengths of time. Following protein extraction, StAR protein levels were determined
using western blot. Primary StAR Antibodies (Santa Cruz) were used. Fold protein expression was
detected using luminol/stable peroxidase detection system (Santa Cruz). Levels were measured through
use of the spot density tool on the FluorChem 8900 Imaging System and each band was adjusted for local
background.
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FIGURE 3

318 bp
324 bp

b – p < 0.01 vs.
control
4, 8 –

number of
individual
samples tested
under each
value

Figure 3: AICAR induces increased StAR mRNA levels in dose dependant manner
Bovine adrenal ZF tissue fragments were treated for 1 hour with increasing dosage of AICAR dissolved
in RPMI at 37º C. Following mRNA extraction, StAR mRNA levels were determined using RT-PCR.
Custom StAR primers along with standard 18s primers were used in the DNA amplifications. Fold
mRNA expression was calculated as a ratio of StAR levels compared 18s levels. Amplified DNA levels
were measured through use of the spot density tool on the FluorChem 8900 Imaging System and each
band was adjusted for local background.
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FIGURE 4

318 bp
324 bp

a, b, c, – p < 0.01 vs.
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same time point
5, 8 –

number of
individual
samples tested
under each
value

Figure 4: AICAR induces increased StAR mRNA levels in time dependant manner
Bovine adrenal ZF tissue fragments were treated with RPMI only or 1 mM AICAR dissolved in RPMI at
37º C for increasing lengths of time. Following mRNA extraction, StAR mRNA levels were determined
using RT-PCR. Custom StAR primers along with standard 18s primers were used in the DNA
amplifications. Fold mRNA expression was calculated as a ratio of StAR levels compared 18s levels.
Amplified DNA levels were measured through use of the spot density tool on the FluorChem 8900
Imaging System and each band was adjusted for local background.

24

FIGURE 5

A.
b – p < 0.01 vs.
control of
the same
time point
4, 6, 7 –number of
individual
samples
tested under
each value

B.
a – p < 0.05 vs.
control

b – p < 0.01 vs.
control
4–

number of
individual
samples
tested under
each value

Figure 5: AICAR activates StAR promoter in time and dose dependant manner
H295R cells were transfected with either pGL2 or with both StAR and β-gal plasmids. Cells were then
treated with A) DMEM/F12 only or 1mM AICAR in DMEM/F12 for increasing lengths of time B)
DMEM/F12 with increasing concentrations of AICAR for 1 hour. Cell treatments were all performed at
37º C and 5% CO2. RLUs were calculated by use of luciferase assay reagent and Galacto-Plus β-gal
detection systems (Tropix) and measured using a TD-20/20 luminometer (Turner Designs).
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FIGURE 6

52 kDa

b – p < 0.01 vs.
control
4, 6 –

number of
individual
samples tested
under each
value

Figure 6: AICAR induces increased SF-1 protein levels in dose dependant manner
Bovine adrenal ZF tissue fragments were treated for 1 hour with increasing dosage of AICAR dissolved
in RPMI at 37º C. Following protein extraction, SF-1 protein levels were determined using western blot.
Primary SF-1 Antibodies (Santa Cruz) were used. Fold protein expression was detected using
luminol/stable peroxidase detection system (Santa Cruz). Levels were measured through use of the spot
density tool on the FluorChem 8900 Imaging System and each band was adjusted for local background.
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FIGURE 7

52 kDa

a, b, c, – p < 0.01 vs.
control of the
same time
point
4, 8 –

number of
individual
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tested under
each value

Figure 7: AICAR induces increased SF-1 protein levels in time dependant manner
Bovine adrenal ZF tissue fragments were treated with RPMI only or 1 mM AICAR dissolved in RPMI at
37º C for increasing lengths of time. Following protein extraction, SF-1 protein levels were determined
using western blot. Primary SF-1 Antibodies (Santa Cruz) were used. Fold protein expression was
detected using luminol/stable peroxidase detection system (Santa Cruz). Levels were measured through
use of the spot density tool on the FluorChem 8900 Imaging System and each band was adjusted for local
background.
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FIGURE 8

55 kDa

b – p < 0.01 vs.
control
3, 4, 9, 10 – number of
individual
samples tested
under each
value

Figure 8: AICAR decreases DAX-1 protein levels in dose dependant manner
Bovine adrenal ZF tissue fragments were treated for 1 hour with increasing dosage of AICAR dissolved
in RPMI at 37º C. Following protein extraction, DAX-1 protein levels were determined using western
blot. Primary DAX-1 Antibodies (Santa Cruz) were used. Fold protein expression was detected using
luminol/stable peroxidase detection system (Santa Cruz). Levels were measured through use of the spot
density tool on the FluorChem 8900 Imaging System and each band was adjusted for local background.
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FIGURE 9

55 kDa

a, b, c – p < 0.01 vs.
control of the
same time
point
6, 9, 10 – number of
individual
samples tested
under each
value

Figure 9: AICAR decreases DAX-1 protein levels in time dependant manner
Bovine adrenal ZF tissue fragments were treated with RPMI only or 1 mM AICAR dissolved in RPMI at
37º C for increasing lengths of time. Following protein extraction, DAX-1 protein levels were
determined using western blot. Primary DAX-1 Antibodies (Santa Cruz) were used. Fold protein
expression was detected using luminol/stable peroxidase detection system (Santa Cruz). Levels were
measured through use of the spot density tool on the FluorChem 8900 Imaging System and each band was
adjusted for local background.
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FIGURE 10

214 bp

324 bp
b – p < 0.01 vs.
control
4, 6 –

number of
individual
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value

Figure 10: AICAR decreases DAX-1 mRNA levels in dose dependant manner
Bovine adrenal ZF tissue fragments were treated for 1 hour with increasing dosage of AICAR dissolved
in RPMI at 37º C. Following mRNA extraction, DAX-1 mRNA levels were determined using RT-PCR.
Custom DAX-1 primers along with standard 18s primers were used in the DNA amplifications. Fold
mRNA expression was calculated as a ratio of DAX-1 levels compared 18s levels. Amplified DNA
levels were measured through use of the spot density tool on the FluorChem 8900 Imaging System and
each band was adjusted for local background.
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FIGURE 11

30 kDa

a – p < 0.01 vs. control

b – p < 0.01 vs. a
8–

number of
individual
samples tested
under each
value

Figure 11: Compound C inhibits AICAR induced increase in StAR protein levels
Bovine adrenal ZF tissue fragments were treated for 1 hour with RPMI only, 10 µM Compound C, 1 mM
AICAR, or both together dissolved in RPMI at 37º C. Following protein extraction, StAR protein levels
were determined using western blot. Primary StAR Antibodies (Santa Cruz) were used. Fold protein
expression was detected using luminol/stable peroxidase detection system (Santa Cruz). Levels were
measured through use of the spot density tool on the FluorChem 8900 Imaging System and each band was
adjusted for local background.
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FIGURE 12

52 kDa

a – p < 0.01 vs. control

b – p < 0.01 vs. a
4, 10 – number of
individual
samples tested
under each
value

Figure 12: Compound C inhibits AICAR induced increase in SF-1 protein levels
Bovine adrenal ZF tissue fragments were treated for 1 hour with RPMI only, 10 µM Compound C, 1 mM
AICAR, or both together dissolved in RPMI at 37º C. Following protein extraction, SF-1 protein levels
were determined using western blot. Primary SF-1 Antibodies (Santa Cruz) were used. Fold protein
expression was detected using luminol/stable peroxidase detection system (Santa Cruz). Levels were
measured through use of the spot density tool on the FluorChem 8900 Imaging System and each band was
adjusted for local background.
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FIGURE 13

55 kDa

b – p < 0.01 vs.
control
4, 13, 14 – number of
individual
samples tested
under each
value

Figure 13: Compound C inhibits AICAR induced decrease in DAX-1 protein levels
Bovine adrenal ZF tissue fragments were treated for 1 hour with RPMI only, 10 µM Compound C, 1 mM
AICAR, or both together dissolved in RPMI at 37º C. Following protein extraction, DAX-1 protein
levels were determined using western blot. Primary DAX-1 Antibodies (Santa Cruz) were used. Fold
protein expression was detected using luminol/stable peroxidase detection system (Santa Cruz). Levels
were measured through use of the spot density tool on the FluorChem 8900 Imaging System and each
band was adjusted for local background.
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FIGURE 14
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a – p < 0.01 vs. control

b – p < 0.01 vs. a
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Figure 14: Compound C inhibits IL-6 induced increase in StAR protein levels
Bovine adrenal ZF tissue fragments were treated for 1 hour with RPMI only, 10 µM Compound C, 25
ng/ml IL-6, or both together dissolved in RPMI at 37º C. Following protein extraction, StAR protein
levels were determined using western blot. Primary StAR Antibodies (Santa Cruz) were used. Fold
protein expression was detected using luminol/stable peroxidase detection system (Santa Cruz). Levels
were measured through use of the spot density tool on the FluorChem 8900 Imaging System and each
band was adjusted for local background.
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Table 1: Bovine primers used for RT-PCR
Gene

Sequence

Strand

Bovine StAR

CCTCTCTACAGCGACCAA

Sense

TCGTGAGTGATGACCGTG

Anti-sense

AGGGGACCGTGCTCTTTAAC

Sense

ATGATGGGCCTGAAGAACAG

Anti-sense

Bovine DAX-1
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